Research units - Molecular Cardiology
Molecular Cardiology
Despite major advances in treatment and prevention, cardiovascular diseases (heart attack, stroke, heart failure) remain major causes of premature death and disability in our community. Our research covers the broad spectrum from basic laboratory to clinical and community studies of new strategies for the prevention and treatment of these important diseases.
Research Themes
The mechanisms of action of new treatments for cardiovascular disease
The mechanisms of diseases of heart muscle
Community study of heart failure prevention
Honours and PhD Projects
Aliskiren: cardioprotection by increased bradykinin levels?
Staff
A/Prof Duncan Campbell
A/Prof David Prior
Dr Jennifer Coller
Suang Suang Koid
Publication Highlights
1. Campbell DJ, Kladis A, Zhang Y, Jenkins AJ, Prior DL, Yii M, Kenny JF, Black MJ, Kelly DJ. Increased tissue kallikrein levels in type 2 diabetes. Diabetologia 2010 (in press, accepted November 30, 2009)
2. Campbell DJ, Karam H, Ménard J, Bruneval P, Mullins JJ. Prorenin contributes to angiotensin peptide formation in transgenic rats with rat prorenin expression targeted to the liver. Hypertension 2009;54:1240-1247
3. Campbell DJ, Nussberger J, Stowasser M, Danser AHJ, Morganti A, Frandsen E, Ménard J. Activity assays and immunoassays for plasma renin and prorenin: information provided and precautions necessary for accurate measurements. Clinical Chemistry 2009;55:867-877.
4. Campbell DJ, Xiao HD, Fuchs S, Bernstein KE. Genetic models provide unique insight into angiotensin and bradykinin peptides in the extravascular compartment of the heart in vivo. Clinical and Experimental Pharmacology and Physiology 2009;36:547-553.
5. Campbell DJ. Angiotensin vaccination: what prospect of success? Current Hypertension Reports 2009;11:63-68.
6. Campbell DJ. Critical review of prorenin and (pro)renin receptor research. Hypertension 2008;
7. Xiao HD, Fuchs S, Bernstein E, Li P, Campbell DJ, Bernstein KE. Mice expressing ACE only in the heart show that increased cardiac angiotensin II is not associated with cardiac hypertrophy. American Journal of Physiology Heart and Circulatory Physiology 2008;294:H659-667.
8. Azizi M, Emmanuelli C, Peyrard S, Madeddu P, Alhenc-Gelas F, Campbell DJ. Genetic and dietary control of plasma tissue kallikrein secretion and urinary kinins excretion in man. Journal of Hypertension 2008;26:714-720.
9. Fuchs S, Xiao HD, Hubert C, Michaud A, Campbell DJ, Adams JW, Capecchi MR, Corvol PL, Bernstein KE. The ACE C-terminal catalytic domain is the main site of angiotensin I cleavage in vivo. Hypertension 2008;51:267-74.
10. Campbell DJ, Woodward M, Chalmers JP, Colman SA, Jenkins AJ, Kemp BE, Neal BC, Patel A, MacMahon SW. Perindopril-based blood pressure-lowering therapy reduces amino-terminal-pro-B-type natriuretic peptide in subjects with cerebrovascular disease. Journal of Hypertension